Pandorum Technologies is a leading biotechnology company specializing in tissue engineering and regenerative medicine in india. The company focuses on developing innovative therapeutic solutions to treat critical health conditions such as corneal dystrophies, lung disorders, and liver diseases. Its core offerings include bio-engineered human tissues like cornea and liver, designed for both medical research and therapeutic applications.
Company Overview
Established in 2011 in Bengaluru, India, by Dr. Tuhin Bhowmick and Dr. Arun Chandru, Pandorum Technologies is driven by a vision to merge biology and engineering to create cutting-edge healthcare solutions. The company is dedicated to addressing unmet clinical needs and transforming the future of regenerative medicine.
Unique Approach
Pandorum Technologies uses proprietary technology platforms to develop functional human tissues. Their innovative strategy involves engineering stem cell-derived exosomes to deliver targeted therapeutic molecules. The company also specializes in constructing 3D functional tissues using a combination of cells, hydrogels, and modulators. Advanced techniques such as 3D bioprinting and self-assembly help replicate the natural architecture of human tissues.
Market Impact & Problem Solving
By tackling the global challenge of donor organ shortages, Pandorum is paving the way for bio-engineered tissue alternatives. Their bio-engineered cornea, for example, has the potential to transform the treatment of corneal disorders by reducing reliance on human donors, thereby making treatments more affordable and accessible for patients worldwide.
Collaborations & Achievements
In March 2022, Pandorum Technologies partnered with Wipro Limited to incorporate artificial intelligence into regenerative medicine, which has accelerated the development of advanced therapeutics. Their innovative approach has earned several accolades, including the Top Innovator Award at the ET Startup Awards in 2018.
Sustainability & Innovation
Focusing on sustainable healthcare solutions, Pandorum is developing cell-free therapies for tissue repair and regeneration. Their research into mesenchymal stem cell-derived exosomes for nanotherapy offers a novel, scalable approach in regenerative medicine that may lead to off-the-shelf therapeutic solutions.
Leadership & Founders
Dr. Tuhin Bhowmick, Co-founder & CEO, holds a Ph.D. from the Indian Institute of Science (IISc), Bangalore, and has completed post-doctoral research at the European Molecular Biology Laboratory. His expertise spans biophysics, crystallography, biomaterials, and computational biology. Co-founder & CTO, Dr. Arun Chandru, earned his M.Sc. (Engg.) from IISc, Bangalore, and is recognized among India’s top innovators in biotechnology and healthcare.
Pandorum Technologies exemplifies the dynamic spirit of startupsonrise in India’s biotech sector. With its breakthrough innovations, strategic partnerships, and visionary leadership, the company is not only transforming the landscape of regenerative medicine but also setting a new benchmark for emerging enterprises in the industry.
In conclusion, Pandorum Technologies is at the forefront of redefining regenerative medicine through its advanced bio-engineered tissue solutions. By addressing critical medical needs and embracing cutting-edge technologies, the company continues to contribute significantly to improving patient care and driving innovation in the biotechnology space.
